Table II.
Association between outcome and clinicopathologic characteristics in patients with glioblastoma harboring different genotypes of SNP rs1957106 in NFKBIA.
| Glioblastoma patients | ||||
|---|---|---|---|---|
|
|
||||
| Characteristic | n | CT/TT genotype | CC genotype | P-value |
| Gender | ||||
| Male | 13 | 6 | 7 | 0.647 |
| Female | 11 | 5 | 6 | |
| Age (years) | ||||
| <60 | 19 | 8 | 11 | 0.668 |
| ≥60 | 5 | 2 | 3 | |
| Surgery | ||||
| Total | 20 | 8 | 12 | 0.563 |
| Subtotal | 4 | 2 | 2 | |
| Radiotherapy | 24 | All | All | - |
| Chemotherapy | ||||
| Temozolomide | 14 | 6 | 8 | 0.500 |
| Me-CCNU+VM26 | 10 | 4 | 6 | |
| Tumor size (cm) | ||||
| <5 | 17 | 7 | 10 | 0.643 |
| ≥5 | 7 | 3 | 4 | |
NFKBIA, nuclear factor-κB inhibitor alpha. P-values were obtained with Fisher’s exact test.